News Archives - QualityStocks

FridayApr 10, 2026 11:15 am

Frontieras North America Inc. Unlocks Value in America’s Energy Future

Frontieras is developing breakthrough technologies that convert abundant solid hydrocarbons such as coal into cleaner fuels, hydrogen and industrial energy products. Central to this strategy is the company’s patented FASForm(TM) Solid Carbon Fractionation process. The company has not only developed its technology but is moving toward commercialization. Frontieras North America is emerging as a noteworthy innovator and attractive potential investment opportunity by addressing one of the most critical challenges facing modern technology: the rapidly growing demand for reliable, affordable electricity. As artificial intelligence (“AI”) and data-intensive computing expand, global electricity demand is projected to soar, with some analysts estimating AI-related…

FridayApr 10, 2026 10:30 am

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Advances Ukraine Defense Initiatives as Electronic Warfare Reshapes Battlefield

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF)and may include paid advertising. The war in Ukraine has demonstrated how electronic warfare can directly influence battlefield outcomes. The ability to interpret spatial data, maintain situational awareness and operate effectively in degraded signal environments is becoming increasingly important. SPARC AI has appointed a ground referral partner connected to Ukraine, a move intended to strengthen its engagement within the region and support potential deployment of its spatial intelligence capabilities. Electronic warfare has become one of the defining elements of modern conflict in Ukraine, where signal disruption, drone countermeasures and navigation…

FridayApr 10, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion

LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers The company’s acquisition of Liora Technologies introduces a complementary therapy platform with recurring revenue potential These updates underscore LIXTE’s broader strategy: integrating drug development and med-tech innovation to redefine cancer treatment LIXTE Biotechnology (NASDAQ: LIXT) is executing a differentiated strategy in oncology, extending beyond traditional drug development into a more integrated and multi-dimensional approach to cancer care. With the company’s lead clinical candidate, LB-100, advancing through trials and the addition of Liora Technologies to its platform, they are positioning themselves at the nexus of pharmaceutical…

FridayApr 10, 2026 9:00 am

Rail Vision Ltd. (NASDAQ: RVSN) Positions AI-Powered Collision Avoidance Tech as Solution to Rail Safety Mandates

The National Transportation Safety Board (“NTSB”) has intensified its focus on collision-prevention technologies following multiple rail incidents. Rail Vision’s proprietary sensor systems are designed to address key railway safety challenges by combining advanced imaging technologies with artificial intelligence and deep learning algorithms. The company’s technology is also designed to integrate with existing rail infrastructure, providing flexibility for operators seeking to upgrade safety capabilities without requiring extensive system overhauls. Rail-safety regulators are increasingly calling for advanced collision-avoidance systems as rail networks grow more complex, and Rail Vision’s (NASDAQ: RVSN, FSE: C80) artificial-intelligence (“AI”)-powered electro-optical sensors are emerging as a direct technological…

ThursdayApr 09, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments The company recently strengthened its position through a strategic partnership with Liora Technologies and the expansion of clinical trials These developments highlight Lixte’s broader mission: To improve cancer outcomes through innovation, combination-based therapeutic strategies Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with…

ThursdayApr 09, 2026 9:45 am

American Fusion(TM) Inc. (AMFN) Talks with Global Industrial Organization, Advancing Supply Chain Strategy

American Fusion(TM) is negotiating a long-term supply framework for helium-3 and deuterium, the fuels used in its Texatron(TM) fusion system. Securing reliable fuel sources is a critical step in fusion commercialization, particularly given the scarcity of helium-3. The company operates through Kepler Fusion Technologies, its wholly owned subsidiary developing the Texatron(TM) reactor platform. A modular deployment strategy includes 5-MW and 100-MW reactor designs, aimed at scalable power generation. The discussions reflect broader efforts to build supply chains, engineering partnerships, and infrastructure needed for commercial fusion systems. American Fusion(TM) (OTC: AMFN), an advanced energy platform company focused on the development and…

ThursdayApr 09, 2026 9:00 am

Capital Flows into Orbit as Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) Targets the Space Economy’s Backbone

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF)and may include paid advertising. Planet Ventures has initiated its entry into the space sector through strategic investments in orbital energy infrastructure and lunar development initiatives. The company’s investment in Mantis Space aligns with emerging demand for in-space power systems supporting satellites, data centers, and lunar operations. The appointment of Tansu Yegen as strategic advisor and full repayment of convertible debentures signal an increasingly active posture as the company pursues space sector opportunities. The global space economy is entering a new phase, shifting from government-led exploration toward commercially driven infrastructure…

WednesdayApr 08, 2026 10:30 am

BluSky AI Inc. (BSAI) Outlines Strategy to Tackle GPU Bottlenecks with Modular Distributed Neocloud Infrastructure

BluSky AI’s business plan includes rapidly deploying SkyMod data centers to meet growing demand for high-performance AI infrastructure The company operates at the intersection of modular data center design, energy optimization, and GPU-as-a-Service delivery The latest updates underscore the company’s broader goal: To empower organizations with flexible, scalable AI infrastructure without compromise BluSky AI (OTC: BSAI) is strategically positioning itself at the forefront of a major shift in artificial intelligence infrastructure, where flexibility and predictable access to compute resources are becoming mission critical. With AI workloads increasing at unprecedented rates, organizations are changing their outlook on traditional hyperscale cloud providers…

WednesdayApr 08, 2026 10:00 am

QualityStocksNewsBreaks – Frontieras North America Highlights Antifragile Energy Strategy as Global Markets Face Historic Disruption

CEO Matthew T. McKean outlines Mason County as proof point for scalable, domestically sourced energy model built to benefit from volatility Frontieras North America CEO Matthew T. McKean, in a newly released blog, details how recent global energy disruptions have exposed the structural weakness of crude-dependent systems while reinforcing the need for a more resilient—and antifragile—approach to energy production. As volatility drives sharp increases in diesel, naphtha and fertilizer prices, McKean emphasizes that the company’s FASForm platform is designed with a fundamentally different architecture: low, fixed-cost domestic coal feedstock paired with outputs priced against global markets, allowing revenues to rise…

WednesdayApr 08, 2026 9:45 am

From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research

Cancer research often relies on massive and complex datasets, which can take time and effort to sift through manually. The proprietary PDAOAI platform from Oncotelic Therapeutics helps with this problem as it was designed to analyze large biomedical datasets to extract meaningful signals and help researchers. The company has also curated a detailed TGF-β literature corpus containing 125,000+ PubMed abstracts that represents all of the scientific knowledge related to TGF-β. This has now expanded to >20M abstracts representing the totality of scientific literature. Cancer research is crucial for understanding, diagnosing, treating, and preventing the disease. However, this research often relies…

Site Search

Company Search

Category: News